Rivals race to develop new biotech asthma drugs

March 18, 2014 12:55 PM

14 0

Rivals race to develop new biotech asthma drugs

LONDON (Reuters) - Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

Britain's GlaxoSmithKline, the leader in asthma treatments since launching its Ventolin inhaler in 1969, is in the vanguard but faces competition from the likes of Roche, AstraZeneca, Sanofi and Teva.

Read more

To category page

Loading...